Medical University of South Carolina, Charleston;
Ralph H. Johnson VA Medical Center, Charleston;
Loyola University Stritch School of Medicine and Cardinal Bernardin Cancer Center, Maywood, Ill
Objective: Studies have demonstrated an advantage in locoregional control and overall survival when cisplatin, used as a radiosensitizer, was added to standard postoperative radiation therapy (RT) in patients with head and neck cancer. This combination therapy has also been associated with significant adverse effects. A newer chemotherapeutic agent, docetaxel, seems to be as effective with fewer adverse effects. In addition, this agent may stimulate the immune system. Our studies assessed whether treatment with combined docetaxel and RT stimulates the immune function in patients with head and neck cancer.
Ghegan MD, Young MRI, Clark J, Veatch LM, Lathers DMR. P117 Immunologic Effects of Combined Docetaxel and Radiation Therapy. Arch Otolaryngol Head Neck Surg. 2006;132(8):888. doi:10.1001/archotol.132.8.888-a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: